Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb;52(1):1-4.
doi: 10.1002/jppr.1799. Epub 2022 Feb 10.

Pandora's box: Paxlovid, prescribing, pharmacists and pandemic

Jason A Roberts  1   2   3   4 , Alison Duncan  5 , Kelly A Cairns  5
Affiliations
Editorial

Pandora's box: Paxlovid, prescribing, pharmacists and pandemic

Jason A Roberts et al. J Pharm Pract Res. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JAR and KAC are members of the Australian National COVID‐19 Clinical Evidence Taskforce. JAR has provided consultancy for Pfizer and MSD in the last 3 years. JAR is an Associate Editor of the JPPR.

References

    1. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN‐COV antibody combination and outcomes in outpatients with Covid‐19. N Engl J Med 2021; 385(23): e81. - PMC - PubMed
    1. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid‐19 in outpatients. N Engl J Med 2021; 386(4): 305–15. - PMC - PubMed
    1. Gupta A, Gonzalez‐Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid‐19 with SARS‐CoV‐2 neutralizing antibody sotrovimab. N Engl J Med 2021; 385(21): 1941–50. - PubMed
    1. National COVID‐19 Clinical Evidence Taskforce [Internet] . Australian guidelines for the clinical care of people with COVID‐19 [updated 2022 Jan 31]. Available from <https://covid19evidence.net.au/#living‐guidelines>. Accessed 01 Feb 2022.
    1. Takashita E, Kinoshita N, Yamayoshi S, Sakai‐Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of antibodies and antiviral drugs against Covid‐19 omicron variant. N Engl J Med 2022. doi:10.1056/NEJMc2119407 - DOI - PMC - PubMed

Publication types